News Release

Frankincense provides relief to arthritis sufferers

Peer-Reviewed Publication

BMC (BioMed Central)

An enriched extract of the 'Indian Frankincense' herb Boswellia serrata has been proven to reduce the symptoms of osteoarthritis. Research published today in BioMed Central's open access journal Arthritis Research & Therapy has shown that patients taking the herbal remedy showed significant improvement in as little as seven days.

Osteoarthritis is the most common form of arthritis; it commonly affects weight-bearing joints such as the knees and hips, along with the hands, wrists, feet and spine. The symptoms include pain, stiffness and limited movement. This randomised, double-blinded, placebo-controlled trial of 70 patients will be of great interest to sufferers, especially those who don't get adequate relief from existing treatments.

The study was led by Siba Raychaudhuri, a faculty member of the University of California, Davis, in the United States. According to Raychaudhuri, "The high incidence of adverse affects associated with currently available medications has created great interest in the search for an effective and safe alternative treatment". The extract the authors used was enriched with 30% AKBA (3-O-acetyl-11-keto-beta-boswellic acid), which is thought to be the most active ingredient in the plant. Raychaudhuri said, "AKBA has anti-inflammatory properties, and we have shown that B. serrata enriched with AKBA can be an effective treatment for osteoarthritis of the knee". This is a proprietary product developed by Laila Nutraceuticals.

B. serrata has been used for thousands of years in the Indian system of traditional medicine known as 'Ayurveda'. This study is the first to prove that an enriched extract of the plant can be used as a successful treatment.

The same authors have previously tested the safety of their remedy in animal experiments. They say that, "In this study, the compound was shown to have no major adverse effects in our osteoarthritis patients. It is safe for human consumption and even for long-term use".

###

Notes to Editors

1. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin(R) for treatment of osteoarthritis of the knee
Krishanu Sengupta, Krishnaraju V Alluri, Andey Rama Sathis, Simanchala Mishra, Trimurtulu Golakoti, Kadainti VS Sarma, Dipak Dey and Siba P Raychaudhuri
Arthritis Research & Therapy (in press)

During embargo, article available here: http://arthritis-research.com/imedia/1806060114163435_article.pdf
After the embargo, article available at journal website: http://arthritis-research.com/

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication

2. Arthritis Research & Therapy is an international, peer-reviewed online and print journal, publishing original research, reviews, commentaries and reports. Studies relate to the rationale and treatment of arthritis, autoimmune disease and diseases of bone and cartilage. The journal is edited by Prof Peter E Lipsky (USA) and Prof Sir Ravinder N Maini (UK) and has an Impact Factor of 4.04.

3. BioMed Central (http://www.biomedcentral.com/) is an independent online publishing house committed to providing immediate access without charge to the peer-reviewed biological and medical research it publishes. This commitment is based on the view that open access to research is essential to the rapid and efficient communication of science.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.